NASDAQ:CLRBCellectar Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cellectar Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.41 +0.07 (+5.22 %) (As of 07/3/2020 01:32 PM ET) Add Compare Share Today's Range$1.38Now: $1.41▼$1.4850-Day Range$1.03MA: $1.31▼$1.5152-Week Range$1.01Now: $1.41▼$3.33Volume1.09 million shsAverage Volume1.14 million shsMarket Capitalization$13.25 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.40, Cellectar Biosciences has a potential upside of 283.0% from its current price of $1.41.Amount of Analyst CoverageCellectar Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesCellectar Biosciences has received 219 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCellectar Biosciences has received 187 “underperform” votes. (Add your “underperform” vote.)Community SentimentCellectar Biosciences has received 53.94% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote “Outperform” if you believe CLRB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $124,442.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.26% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 15.66% of the stock of Cellectar Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.47) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectar Biosciences has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.97 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLRB Previous Symbol CUSIPN/A CIK1279704 Webwww.cellectar.com Phone608-441-8120Debt Debt-to-Equity Ratio0.10 Current Ratio2.58 Quick Ratio2.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book1.68Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-14,090,000.00 Net MarginsN/A Return on Equity-152.18% Return on Assets-103.56%Miscellaneous Employees7 Outstanding Shares9,400,000Market Cap$13.25 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NASDAQ:CLRB Rates by TradingView Receive CLRB News and Ratings via Email Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions How has Cellectar Biosciences' stock been impacted by COVID-19 (Coronavirus)? Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLRB stock has decreased by 21.7% and is now trading at $1.41. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cellectar Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectar Biosciences. When is Cellectar Biosciences' next earnings date? Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cellectar Biosciences. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences Inc (NASDAQ:CLRB) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.07. View Cellectar Biosciences' earnings history. When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work? Cellectar Biosciences's stock reverse split before market open on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for CLRB? 5 brokers have issued 1-year target prices for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Cellectar Biosciences' stock price to reach $5.40 in the next year. This suggests a possible upside of 283.0% from the stock's current price. View analysts' price targets for Cellectar Biosciences. Has Cellectar Biosciences been receiving favorable news coverage? News coverage about CLRB stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellectar Biosciences earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Cellectar Biosciences. Who are some of Cellectar Biosciences' key competitors? Some companies that are related to Cellectar Biosciences include Vascular Biogenics (VBLT), Aerpio Pharmaceuticals (ARPO), Infinity Pharmaceuticals (INFI), Cumberland Pharmaceuticals (CPIX), Processa Pharmaceuticals (PCSA), Acasti Pharma (ACST), Akorn (AKRXQ), Diffusion Pharmaceuticals (DFFN), Seelos Therapeutics (SEEL), OncoSec Medical (ONCS), Addex Therapeutics (ADDXF), Merrimack Pharmaceuticals (MACK), Zosano Pharma (ZSAN), Aileron Therapeutics (ALRN) and Edesa Biotech (EDSA). View all competitors. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM). Who are Cellectar Biosciences' key executives? Cellectar Biosciences' management team includes the following people: Mr. James V. Caruso, Pres, CEO & Director (Age 60)Mr. Jarrod Longcor, Chief Bus. Officer (Age 46)Mr. Charles T. Bernhardt, Interim Chief Financial Officer (Age 58)Gregory J. Lynch, Sec. What is Cellectar Biosciences' stock symbol? Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB." How do I buy shares of Cellectar Biosciences? Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cellectar Biosciences' stock price today? One share of CLRB stock can currently be purchased for approximately $1.41. How big of a company is Cellectar Biosciences? Cellectar Biosciences has a market capitalization of $13.25 million. The biopharmaceutical company earns $-14,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe. What is Cellectar Biosciences' official website? The official website for Cellectar Biosciences is www.cellectar.com. How can I contact Cellectar Biosciences? Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
